JTFM, Slvr first I'd like to thank you for all the valuable insights you've been sharing the last few years. I've been following ANI since 2015 with ins and outs and have build a sizeable position (according to my means) since 2 years now. This is certainly partially thanks to the valuable information you've been sharing all these years. So thank you for that. I would be interested to have your thoughts on the following: with MNK being in so much trouble there's a good chance that they'll have to sell their assets, Acthar included. Should Acthar be sold to a big pharma with a large and experienced sales team, existing relationships with prescribers, etc wouldn't it be a very concrete threat for ANI ? This might not happen overnight but it could have a strong impact on Cortrophin's future growth. Any thoughts ? Many thanks in advance.
Market Data 
Markets 
AI
